Identification of potential crucial genes and biomarkers from neutrophils in sepsis using bioinformatics analysis

利用生物信息学分析鉴定脓毒症中性粒细胞中潜在的关键基因和生物标志物

阅读:1

Abstract

Sepsis is a complex series of immune responses to infection and is commonly associated with acquired immunodeficiency. The current study aimed to identify the biomarkers of sepsis. Differential expression analysis and protein-protein interaction analysis were conducted to explore potential biomarkers. Gene Ontology enrichment analysis and Kyoto Encyclopedia of Genes and Genomes analysis were performed to explore potential mechanisms. The Immune Cell Abundance Identifier website was utilized to evaluate immune cell infiltration in the whole blood. Receiver operating characteristic curve and area under the curve were applied to compare the prognostic accuracy of hub genes. Six genes were selected via differentially expressed gene analysis and protein-protein interaction analysis. Furthermore, CTSD, GADD45A, MAPK14, MMP9, and VIM were selected via validation analysis of independent datasets. Immune infiltration analysis showed that CTSD, GADD45A, MAPK14, MMP9, and VIM may regulate immune cells via neutrophils. Patients with sepsis had a significantly higher expression of CTSD, GADD45A, MAPK14, MMP9, and VIM than normal health controls. The area under the curve of CTSD, GADD45A, MAPK14, MMP9, and VIM were 0.90 (0.83-0.97), 0.89 (0.81-0.96), 0.91 (0.84-0.87), 0.95 (0.91-1.00), and 0.95 (0.91-1.00), respectively. According to the validation result of RT-PCR, only MAPK14 was significantly upregulated compared with controls, which was concordant with the bioinformatics analysis results. This study identified several potential diagnostic genes including CTSD, GADD45A, MAPK14, MMP9, and VIM. These genes may regulate the expression of immune cells via neutrophils in the development of sepsis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。